Evidence map›Paper›PMID 24753981›Full record

ReviewAmerican journal of nuclear medicine and molecular imaging2014

Modeling and imaging cardiac sympathetic neurodegeneration in Parkinson's disease.

Valerie Joers, Marina E Emborg

Open access · greenAbstract readReview
PubMed Full text at PMC
In one paragraph

Review in American journal of nuclear medicine and molecular imaging, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Genetic and Environmental Factors Influence the Pleomorphy ofInternational journal of molecular sciences · 2021
    Review
  5. [EJNMMI research · 2020
    Article
  6. Article
  7. Autonomic dysfunction in Parkinson disease and animal models.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2019
    Review
  8. Article
  9. Review
  10. Parkinson's Disease and Its Management: Part 5: Treatment of Nonmotor Complications.P & T : a peer-reviewed journal for formulary management · 2015
    Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Valerie JoersPreclinical Parkinson's Research Program, Wisconsin National Primate Research Center, University of Wisconsin-Madison 1220 Capitol Court, Madison, WI 53715, USA ; Neuroscience Training Program, University of Wisconsin-Madison Madison, WI 53715, USA.
Marina E EmborgPreclinical Parkinson's Research Program, Wisconsin National Primate Research Center, University of Wisconsin-Madison 1220 Capitol Court, Madison, WI 53715, USA ; Neuroscience Training Program, University of Wisconsin-Madison Madison, WI 53715, USA ; Department of Medical Physics, 1111 Highland Avenue, University of Wisconsin-Madison Madison WI 53705, USA.
University of Wisconsin–Madison · US

Funding

WNPRC Supplemental Request for Nonhuman Primate Enclosures to Equip HIV/AIDS-Related Research FacilitiesP51OD011106 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI Dorota A. Grejner-Brzezinska · 2012 to 2026
$150.7M
ZOLEDRONATE PREVENTS BONE LOSS IN OVARIECTOMIZED RHESUS MONKEYSP51RR000167 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · PI WATKINS, DAVID I · 1985 to 2011
$106.7M
INSTITUTIONAL CTSA (UW-MADISON): CLINICAL TRIALSUL1RR025011 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · PI DREZNER, MARC KENNETH · 2007 to 2011
$29.5M
NCRR NIH HHS P51 RR000167NCRR NIH HHS UL1 RR025011NIH HHS P51 OD011106
6 · The paper itself

Abstract

Parkinson's disease (PD) is currently recognized as a multisystem disorder affecting several components of the central and peripheral nervous system. This new understanding of PD helps explain the complexity of the patients' symptoms while challenges researchers to identify new diagnostic and therapeutic strategies. Cardiac neurodegeneration and dysautonomia affect PD patients and are associated with orthostatic hypotension, fatigue, and abnormal control of electrical heart activity. They can seriously impact daily life of PD patients, as these symptoms do not respond to classical anti-parkinsonian medications and can be worsened by them. New diagnostic tools and therapies aiming to prevent cardiac neurodegeneration and dysautonomia are needed. In this manuscript we critically review the relationship between the cardiovascular and nervous system in normal and PD conditions, current animal models of cardiac dysautonomia and the application of molecular imaging methods to visualize cardiac neurodegeneration. Our goal is to highlight current progress in the development of tools to understand cardiac neurodegeneration and dysautonomia and monitor the effects of novel therapies aiming for global neuroprotection.

Indexed as

11C-MHED18F-FDAcardiac dysautonomiaParkinson’s diseasePositron emission tomographySPECTsympathetic nervous system

Identifiers

PMID24753981
PMCPMC3992208
OpenAlexW1820647063

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.